How to treat tumefactive demyelinating disease?SIFFRIN, Volker; MÜLLER-FORELL, Wibke; VON PEIN, Harald et al.Multiple sclerosis. 2014, Vol 20, Num 5, pp 631-633, issn 1352-4585, 3 p.Article

A novel method for calculating prevalence of multiple sclerosis in AustraliaPALMER, Andrew J; HITCHENS, Peta L; SIMPSON, Steve et al.Multiple sclerosis. 2013, Vol 19, Num 13, pp 1704-1711, issn 1352-4585, 8 p.Article

Disease-modifying treatments for progressive multiple sclerosisCOMI, Giancarlo.Multiple sclerosis. 2013, Vol 19, Num 11, pp 1428-1436, issn 1352-4585, 9 p.Article

Pathophysiology of multiple sclerosis and the place of teriflunomideGOLD, R; WOLINSKY, J. S.Acta neurologica scandinavica. 2011, Vol 124, Num 2, pp 75-84, issn 0001-6314, 10 p.Article

Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosisCHITNIS, T; TENEMBAUM, S; KORNBERG, A et al.Multiple sclerosis. 2012, Vol 18, Num 1, pp 116-127, issn 1352-4585, 12 p.Article

Severe relapse of multiple sclerosis during plasma exchange treatmentMATZKE, Burkhard; METZE, Christoph; WINKELMANN, Alexander et al.Multiple sclerosis. 2011, Vol 17, Num 6, pp 759-762, issn 1352-4585, 4 p.Article

Performance of the Swanton multiple sclerosis criteria for dissemination in spaceNIELSEN, J. M; UITDEHAAG, Bmj; KORTEWEG, T et al.Multiple sclerosis. 2010, Vol 16, Num 8, pp 985-987, issn 1352-4585, 3 p.Article

PROGRESS IN THE DEVELOPMENT OF NEW DRUGS IN ALZHEIMER'S DISEASEPIAU, A; NOURHASHEMI, F; HEIN, C et al.The Journal of nutrition, health & aging. 2011, Vol 15, Num 1, pp 45-57, issn 1279-7707, 13 p.Article

Daclizumab in treatment of multiple sclerosis patientsALI, E. N; HEALY, B. C; STAZZONE, L. A et al.Multiple sclerosis. 2009, Vol 15, Num 2, pp 272-274, issn 1352-4585, 3 p.Article

Severe haematological complications during treatment with natalizumabMIDAGLIA, L; RODRIGUEZ RUIZ, M; MUNOZ-GARCIA, D et al.Multiple sclerosis. 2012, Vol 18, Num 11, pp 1644-1646, issn 1352-4585, 3 p.Article

Incorporation of an interferon-β neutralizing antibody assay into routine clinical practiceFARRELL, R. A; ESPASANDIN, M; LAKDAWAIA, N et al.Multiple sclerosis. 2011, Vol 17, Num 11, pp 1333-1340, issn 1352-4585, 8 p.Article

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosisHOLMEN, Carolina; PIEHL, Fredrik; LYCKE, Jan et al.Multiple sclerosis. 2011, Vol 17, Num 6, pp 708-719, issn 1352-4585, 12 p.Article

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumabSØRENSEN, Soelberg; HYLDGAARD JENSEN, Poul Erik; GOLD, Ralf et al.Multiple sclerosis. 2011, Vol 17, Num 9, pp 1074-1078, issn 1352-4585, 5 p.Article

A method for evaluating treatment switching criteria in multiple sclerosisHEALY, Brian C; GLANZ, Bonnie I; STANKIEWICZ, James et al.Multiple sclerosis. 2010, Vol 16, Num 12, pp 1483-1489, issn 1352-4585, 7 p.Article

Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?LONERGAN, Roisin; KINSELLA, Katie; DUGGAN, Marguerite et al.Multiple sclerosis. 2009, Vol 15, Num 12, pp 1528-1531, issn 1352-4585, 4 p.Article

Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis StudyMINDEN, S; HOAGLIN, D; JUREIDINI, S et al.Multiple sclerosis. 2008, Vol 14, Num 5, pp 640-655, issn 1352-4585, 16 p.Article

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stoppedRISPENS, Theo; VENNEGOOR, Anke; JAN WOLBINK, Gert et al.Multiple sclerosis. 2012, Vol 18, Num 6, pp 899-901, issn 1352-4585, 3 p.Article

Potential Health Care Cost Savings Associated With Early Treatment of Multiple Sclerosis Using Disease-Modifying TherapyCURKENDALL, Suellen M; CHENG WANG; JOHNSON, Barbara H et al.Clinical therapeutics. 2011, Vol 33, Num 7, pp 914-925, issn 0149-2918, 12 p.Article

Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control studyLANGER-GOULD, A; ALBERS, K. B; VAN DEN EEDEN, S. K et al.Multiple sclerosis. 2010, Vol 16, Num 7, pp 855-861, issn 1352-4585, 7 p.Article

Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosisPERUMAL, Jai S; FOO, Farng; COOK, Perry et al.Multiple sclerosis. 2012, Vol 18, Num 8, pp 1197-1199, issn 1352-4585, 3 p.Article

Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosisSELLEBJERG, F; HESSE, D; LIMBORG, S et al.Multiple sclerosis. 2013, Vol 19, Num 2, pp 179-187, issn 1352-4585, 9 p.Article

Do not treat from CIS onset: evaluate disease course and prognosis first - YesBUNYAN, Reem F; PITTOCK, Sean J.Multiple sclerosis. 2012, Vol 18, Num 4, pp 391-393, issn 1352-4585, 3 p.Article

Effect of BG-I2 on contrast-enhanced lesions in patients with relapsing― remitting multiple sclerosis: subgroup analyses from the phase 2b studyKAPPOS, Ludwig; GOLD, Ralf; MELUZINOVA, Eva et al.Multiple sclerosis. 2012, Vol 18, Num 3, pp 314-321, issn 1352-4585, 8 p.Article

Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugsLU, E; DAHLGREN, L; SADOVNICK, A. D et al.Multiple sclerosis. 2012, Vol 18, Num 4, pp 460-467, issn 1352-4585, 8 p.Article

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosisHAVRDOVA, E; ZIVADINOV, R; BERGSLAND, N et al.Multiple sclerosis. 2009, Vol 15, Num 8, pp 965-976, issn 1352-4585, 12 p.Article